Vera Therapeutics Presents Positive TRUTAKNA Data in IgA Nephropathy
Source: bi ·
Vera Therapeutics announced positive results from the ORIGIN 3 trial of TRUTAKNA in adults with IgA nephropathy, presented at ASN Kidney Week 2026 and published in The New England Journal of Medicine. The trial evaluated the efficacy of TRUTAKNA in preventing disease progression in patients with primary IgA nephropathy.